表紙
市場調査レポート

核画像診断 (PET・SPECT装置) の米国市場 - 分析と予測

MediPoint: Nuclear Imaging - US Analysis and Market Forecasts

発行 GlobalData 商品コード 331271
出版日 ページ情報 英文 233 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
核画像診断 (PET・SPECT装置) の米国市場 - 分析と予測 MediPoint: Nuclear Imaging - US Analysis and Market Forecasts
出版日: 2014年12月31日 ページ情報: 英文 233 Pages
概要

当レポートでは、米国の核画像診断(PET・SPECT装置など)関連の市場について分析し、疾患の概要や市場構造、現在のアンメットニーズ、主な市場促進・抑制要因、今後の市場機会、現在治験中の主要製品、市場動向(過去3年間の実績値と今後7年間の予測値)、製品カテゴリー別の詳細動向、主要企業のプロファイルなどを調査しております

第1章 目次

第2章 イントロダクション

第3章 産業概要

  • 放射性画像技術
    • ポジトロン放射断層撮影 (PET)
    • 単光子放出コンピュータ断層撮影 (SPECT)
    • 平面シンチグラフィ
    • ハイブリッド型画像診断法
  • 核画像技術の臨床現場での用途
    • がん
    • 心臓病
    • 神経症
    • 感染症および炎症
  • 核画像診断技術の長所・短所
  • 市場へのアクセス
    • 製品のライフサイクル
    • 購入意思決定
    • 設備リース
    • PET/MRIによるPET/CTの交換
  • 償還
  • 処置の動向
  • 規制上の課題/リコール
  • M&Aおよび主な提携
  • 経済的影響

第4章 アンメットニーズ

  • 概要
  • 新技術に対する医療費償還の改善
  • 強制力のある臨床ガイドラインの欠如
  • 患者の快適性および便宜
  • 放射線曝露量の減少
  • スキャナの性能の改善
  • 画像処理ソフトウェアの改善
  • ハイブリッド型画像処理における人為的リスクの増加
  • 新しい放射性トレーサに対する需要
  • 設計プロセスへの臨床的入力の改善

第5章 市場機会の分析

  • より安くて簡単な核画像装置
  • 開発途上国でのSPECT/CT
  • テレラジオロジーサービスへの需要の増加

第6章 市場の促進要因および障壁

  • 促進要因:高齢者および有病者数の増加
  • 促進要因:医師の認知度の向上
  • 促進要因:防衛的医療
  • 促進要因:患者の認識
  • 促進要因:任意照会
  • 促進要因:新しい造影剤
  • 促進要因:がん診断検査の需要拡大
  • 促進要因:コンパニオン診断検査
  • 障壁:競合製品の有効性の研究
  • 障壁:医療費償還法案
  • 障壁:途上国市場での核画像診断の需要拡大
  • 障壁:不要な画像診断を減らすための保険会社のロビー活動
  • 障壁:EMRの保険調査の対象者の拡大
  • 障壁:妥当性基準の使用増加
  • 障壁:不要な処置を減らす診療ガイドライン
  • 障壁:画像設備の認定
  • 障壁:核医学スキルの不足
  • 障壁:装置・試薬の高コスト性
  • 障壁:放射性医薬品のコスト・供給面での困難性
  • 障壁:医療機器への物品税
  • 障壁:病院の整理統合

第7章 競合評価

  • 概要
  • PET専用装置
    • 概要
    • 製品プロファイル
    • SWOT分析
  • PET/CT装置
  • PET/MRI装置
  • SPECT専用装置
  • SPECT/CT装置
  • PET/超音波およびSPECT/超音波装置

第8章 パイプライン製品の評価

  • 概要
  • 発展段階によるパイプライン製品
  • 製品プロファイル(全11製品)

第9章 注目の臨床検査

  • 概要
  • 治験のプロファイル

第10章 現在および将来の主要企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • DDD-Diagnostic
    • Digirad
    • GE Healthcare
    • GVI Medical Devices
    • Mediso Medical Imaging Systems
    • NeuroLogica
    • Neusoft Medical Systems
    • NuCare Medical Systems
    • Oncovision
    • Philips Healthcare
    • 島津製作所
    • Siemens Healthcare
    • SurgicEye
    • 東芝メディカルシステムズ
    • その他の企業

第11章 市場の展望

  • 企業市場シェア分析
  • 地域別

第12章 付録

目次
Product Code: GDME1128CFR

This report examines how new technologies can emerge in the face of economic pressures that may affect the demand for nuclear imaging, and how healthcare reforms are impacting nuclear medicine. The advent of hybrid imaging has enabled PET/CT imaging to undergo explosive growth. However, this has been at the cost of an increased demand on struggling healthcare budgets. PET and SPECT imaging are well established techniques within nuclear imaging, and are the main focus of this report PET imaging uses Positron Emitting radioactive tracers with a short half life, to image metabolically active organs PET combined with CT allows precise anatomical imaging of the body, identifying diseased areas depending upon the tracer used PET/CT is most often used for cancer diagnosis PET/MRI is a new technique that was introduced to reduce patient exposure to radiation PET only systems are now generally considered obsolete, due to the superior imaging quality of PET/CT

PET/MRI is expected to remain a nascent segment in the US nuclear imaging market, far behind well-established and generally well regarded PET/CT scanners. No replacement sales are expected during the forecast period, and the volume of systems sold (only one per year) is expected to remain low, due to physician skepticism of the clinical validity of this hybrid modality.

Scope

  • An overview of Nuclear Imaging, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized the US Nuclear Imaging market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
  • Investigation of current and future market competition for Nuclear Imaging.
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the Nuclear Imaging sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

  • Understand the trends shaping and driving the US Nuclear Imaging market.
  • Realize device preferences of physicians who have performed the tests already.
  • Access market sizing, forecasts and quantified growth opportunities in the US Nuclear Imaging market through 2018.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
  • What's the next big thing in the US Nuclear Imaging market landscape? Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Industry Overview

  • 3.1. Nuclear Imaging Techniques
    • 3.1.1. Positron Emission Tomography
    • 3.1.2. Single-Photon Emission Computed Tomography
    • 3.1.3. Planar Scintigraphy
    • 3.1.4. Hybrid Imaging
  • 3.2. Clinical Applications of Nuclear Imaging Technology
    • 3.2.1. Cancer
    • 3.2.2. Cardiology
    • 3.2.3. Neurology
    • 3.2.4. Infection and Inflammation
  • 3.3. Advantages and Disadvantages of Nuclear Imaging Technologies
  • 3.4. Market Access
    • 3.4.1. Product Life Cycle
    • 3.4.2. Purchasing Decisions
    • 3.4.3. Equipment Leasing
    • 3.4.4. Replacement of PET/CT by PET/MRI
  • 3.5. Reimbursement
  • 3.6. Procedure Trends
  • 3.7. Regulatory Issues/Recalls
  • 3.8. M&As and Key Partnerships
  • 3.9. Economic Impact

4. Unmet Needs

  • 4.1. Overview
  • 4.2. Improved Reimbursement for New Techniques
  • 4.3. Lack of Binding Clinical Guidelines
  • 4.4. Patient Comfort and Convenience
  • 4.5. Reducing Radiation Exposure
  • 4.6. Improved Scanner Performance
  • 4.7. Image Processing Software Improvements
  • 4.8. Increased Risk of Artifacts in Hybrid Images
  • 4.9. Demand for New Radiotracers
  • 4.10. Improved Clinical Input into the Design Process

5. Market Opportunity Analysis

  • 5.1. Cheaper, Simpler Nuclear Imaging Devices
  • 5.2. SPECT/CT in Developing Countries
  • 5.3. Increased Demand for Teleradiology Services

6. Market Drivers and Barriers

  • 6.1. Driver: Aging Population and Increasing Disease Prevalence
  • 6.2. Driver: Referring Physician Awareness
  • 6.3. Driver: Defensive medicine
  • 6.4. Driver: Patient Awareness
  • 6.5. Driver: Self-Referral
  • 6.6. Driver: New Imaging Agents
  • 6.7. Driver: Increasing Demand for Cancer Diagnostic Tests
  • 6.8. Driver: Companion Diagnostic Testing
  • 6.9. Barrier: Comparative Effectiveness Research
  • 6.10. Barrier: Reimbursement Legislation
  • 6.11. Barrier: Increasing Demand for Nuclear Imaging in Developing Markets
  • 6.12. Barrier: Insurance Company Lobbying to Reduce Unnecessary Imaging
  • 6.13. Barrier: Greater Payer Scrutiny of EMRs
  • 6.14. Barrier: Increased Use of Appropriateness Criteria
  • 6.15. Barrier: Practice Guidelines to Reduce Unnecessary Procedures
  • 6.16. Barrier: Imaging Facility Accreditation
  • 6.17. Barrier: Loss of Nuclear Medicine Skills
  • 6.18. Barrier: High Cost of Instruments and Reagents
  • 6.19. Barrier: Radiopharmaceutical Cost and Supply Difficulties
  • 6.20. Barrier: Medical Device Excise Tax
  • 6.21. Barrier: Hospital Consolidation

7. Competitive Assessment

  • 7.1. Overview
  • 7.2. Dedicated PET Systems
    • 7.2.1. Overview
    • 7.2.2. Product Profile
    • 7.2.3. SWOT Analysis
  • 7.3. PET/CT Systems
    • 7.3.1. Overview
    • 7.3.2. Product Profiles
    • 7.3.3. SWOT Analysis
  • 7.4. PET/MRI Systems
    • 7.4.1. Overview
    • 7.4.2. Product Profile
    • 7.4.3. SWOT Analysis
  • 7.5. Dedicated SPECT Systems
    • 7.5.1. Overview
    • 7.5.2. Product Profile
    • 7.5.3. SWOT Analysis
  • 7.6. SPECT/CT Systems
    • 7.6.1. Overview
    • 7.6.2. Product Profile
    • 7.6.3. SWOT Analysis
  • 7.7. PET/Ultrasound and SPECT/Ultrasound Systems
    • 7.7.1. Overview
    • 7.7.2. Product Profile
    • 7.7.3. SWOT Analysis

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Pipeline by Phases in Development
  • 8.3. Product Profiles
    • 8.3.1. Brain Biosciences CerePET
    • 8.3.2. ECORAD Dual Modality Imager
    • 8.3.3. FMI Technologies ScintiStar PET/CT
    • 8.3.4. IntraMedical Imaging Marginator Beta Camera
    • 8.3.5. INSERT SPECT/MRI
    • 8.3.6. Nucare/Zecotek Photonics New Generation PET Scanning Device
    • 8.3.7. Philips Healthcare PET Alpha Ring Detector
    • 8.3.8. Photo Diagnostic Systems NeuroPET/CT
    • 8.3.9. SynchroPET Breast PET/MRI
    • 8.3.10. SynchroPET Wrist Scanner
    • 8.3.11. SurgicEye SPECT Hybrid

9. Clinical Trials to Watch

  • 9.1. Overview
  • 9.2. Clinical Trial Profiles

10. Current and Future Players

  • 10.1. Overview
  • 10.2. Trends in Corporate Strategy
  • 10.3. Company Profiles
    • 10.3.1. DDD-Diagnostic
    • 10.3.2. Digirad
    • 10.3.3. GE Healthcare
    • 10.3.4. GVI Medical Devices
    • 10.3.5. Mediso Medical Imaging Systems
    • 10.3.6. NeuroLogica
    • 10.3.7. Neusoft Medical Systems
    • 10.3.8. NuCare Medical Systems
    • 10.3.9. Oncovision
    • 10.3.10. Philips Healthcare
    • 10.3.11. Shimadzu
    • 10.3.12. Siemens Healthcare
    • 10.3.13. SurgicEye
    • 10.3.14. Toshiba Medical
    • 10.3.15. Other Companies

11. Market Outlooks

  • 11.1. Company Market Share Analysis
  • 11.2. By Geography

12. Appendix

  • 12.1. Abbreviations
  • 12.2. Bibliography
  • 12.3. Methodology
    • 12.3.1. Overview
    • 12.3.2. Coverage
    • 12.3.3. Secondary Research
  • 12.4. Physicians and Specialists Included in This Study
  • 12.5. Primary Research
    • 12.5.1. Primary Research - Key Opinion Leader Interviews
    • 12.5.2. Expert Panel Validation
    • 12.5.3. Stakeholder Survey
  • 12.6. Forecasting Methodology
  • 12.7. About the Authors
    • 12.7.1. Andrew Thompson, PhD, Senior Analyst
    • 12.7.2. Priya Radhakrishnan, MBA, Director, Medical Devices
    • 12.7.3. Bonnie Bain, PhD, Global Head of Healthcare
  • 12.8. About GlobalData
  • 12.9. Disclaimer

List of Tables

  • Table 1: Applications of Nuclear Imaging
  • Table 2: FDG-PET Diagnostic Accuracy for Specific Cancers
  • Table 3: Potential Clinical Benefits of Hybrid Nuclear Imaging in Cardiology
  • Table 4: Applications of PET Imaging in Non-Cancer Neurology
  • Table 5: Applications of SPECT Imaging in Non-Cancer Neurology
  • Table 6: Characteristics of SPECT, PET, Ultrasound, CT, and MRI
  • Table 7: The Age of Canada's Hospital-Based Medical Technology Inventories, Relative to ECCREI Rules, 2009
  • Table 8: Nuclear Imaging Trends in US, 2012-2020
  • Table 9: Recent Device Recalls in the Nuclear Imaging Market
  • Table 10: Recent Key Events in the Nuclear Imaging Market
  • Table 11: Nuclear Imaging Market Drivers and Barriers
  • Table 12: Duplicate Diagnostic Test Incidence in France, Germany, UK, and US
  • Table 13: Dedicated PET Scanners
  • Table 14: Dedicated PET SWOT Analysis
  • Table 15: PET/CT Scanners
  • Table 16: PET/CT SWOT Analysis
  • Table 17: PET/MRI Systems
  • Table 18: PET/MRI SWOT Analysis
  • Table 19: Dedicated SPECT Systems
  • Table 20: Dedicated SPECT SWOT Analysis
  • Table 21: SPECT/CT Systems
  • Table 22: SPECT/CT SWOT Analysis
  • Table 23: SPECT-Ultrasound Systems
  • Table 24: SPECT/Ultrasound SWOT Analysis
  • Table 25: Nuclear Imaging Pipeline, 2014
  • Table 26: CerePET SWOT Analysis
  • Table 27: ECORAD Dual Modality Imager SWOT Analysis
  • Table 28: ScintiStar PET/CT SWOT Analysis
  • Table 29: Marginator SWOT Analysis
  • Table 30: INSERT SPECT-MRI SWOT Analysis
  • Table 31: Nucare/Zecotek Photonics New Generation PET Scanning Device SWOT Analysis
  • Table 32: PET Alpha Ring Detector
  • Table 33: NeuroPET/CT Scanner SWOT Analysis
  • Table 34: SynchroPET Breast PET/MRI SWOT Analysis
  • Table 35: SynchroPET Wrist Scanner
  • Table 36: SurgicEye SPECT/Ultrasound device SWOT Analysis
  • Table 37: Key Clinical Trials
  • Table 38: Company Profile - DDD-Diagnostic
  • Table 39: DDD-Diagnostic SWOT Analysis
  • Table 40: Company Profile - Digirad
  • Table 41: Digirad SWOT Analysis
  • Table 42: Company Profile - GE Healthcare
  • Table 43: GE Healthcare Product Portfolio
  • Table 44: GE Healthcare SWOT Analysis
  • Table 45: Company Profile - GVI Medical Devices
  • Table 46: GVI Medical Devices SWOT Analysis
  • Table 47: Company Profile - Mediso Medical Imaging Systems
  • Table 48: Mediso Medical Imaging Systems SWOT Analysis
  • Table 49: Company Profile - Neurologica
  • Table 50: Neurologica SWOT Analysis
  • Table 51: Company Profile - Neusoft Medical Systems
  • Table 52: Neusoft Medical Systems SWOT Analysis
  • Table 53: Company Profile - NuCare Medical Systems
  • Table 54: Nucare Medical Systems SWOT Analysis
  • Table 55: Company Profile - Oncovision
  • Table 56: Oncovision SWOT Analysis
  • Table 57: Company Profile - Philips Healthcare
  • Table 58: Philips Healthcare SWOT Analysis
  • Table 59: Company Profile - Shimadzu
  • Table 60: Shimadzu SWOT Analysis
  • Table 61: Company Profile - Siemens Healthcare
  • Table 62: Siemens Healthcare SWOT Analysis
  • Table 63: Company Profile - SurgicEye
  • Table 64: SurgicEye SWOT Analysis
  • Table 65: Company Profile - Toshiba Medical
  • Table 66: Toshiba Medical SWOT Analysis
  • Table 67: Other Companies in the Nuclear Imaging Market, 2014
  • Table 68: US Sales of PET and SPECT Imaging Systems, 2012-2020
  • Table 69: United States Market Value Forecast by Market Sub-segment (2012-2020)
  • Table 70: Primary Research Summary
  • Table 71: Primary Research Participants Affiliation

List of Figures

  • Figure 1: Cyclotron Distribution in 10 Countries
  • Figure 2: Localization of Tumor in Chest Cavity by PET, CT, and PET/CT
  • Figure 3: Mutually Beneficial Effects of PET/MRI Imaging
  • Figure 4: Nuclear Imaging Trends in US, 2012-2020
  • Figure 5: Total Medicare Expenditures for Imaging Services Paid Under the Physician Fee Schedule, 2000-2006
  • Figure 6: Imaging Utilization Rates (Number of Outpatient Visits with MRI/CT per 1,000 Persons), by Year in the US
  • Figure 7: US Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 8: US Sales of PET and SPECT Imaging Systems, 2012-2020
  • Figure 9: United States Market Value Forecast by Market Sub-segment (2012-2020)
  • Figure 10: Primary Research Summary
  • Figure 11: Primary Research Participants Affiliation
Back to Top